239 related articles for article (PubMed ID: 18936605)
1. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
Duet M; Kerkeni S; Sfar R; Bazille C; Lioté F; Orcel P
Clin Nucl Med; 2008 Nov; 33(11):752-6. PubMed ID: 18936605
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
3. [Detection of the primary tumor site in tumor-induced osteomalacia by indium-111 octreotide scintigraphy: a case report].
Takahashi M; Toru S; Ota K; Izumiyama H; Yokota T; Mizusawa H
Rinsho Shinkeigaku; 2008 Feb; 48(2):120-4. PubMed ID: 18326305
[TBL] [Abstract][Full Text] [Related]
4. Localisation of mesenchymal tumours by somatostatin receptor imaging.
Jan de Beur SM; Streeten EA; Civelek AC; McCarthy EF; Uribe L; Marx SJ; Onobrakpeya O; Raisz LG; Watts NB; Sharon M; Levine MA
Lancet; 2002 Mar; 359(9308):761-3. PubMed ID: 11888589
[TBL] [Abstract][Full Text] [Related]
5. Tumor-induced osteomalacia: experience from a South American academic center.
González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
[TBL] [Abstract][Full Text] [Related]
6. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
[TBL] [Abstract][Full Text] [Related]
7. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia.
Nguyen BD; Wang EA
Clin Nucl Med; 1999 Feb; 24(2):130-1. PubMed ID: 9988077
[No Abstract] [Full Text] [Related]
8. Octreotide therapy for tumor-induced osteomalacia.
Seufert J; Ebert K; Müller J; Eulert J; Hendrich C; Werner E; Schuüze N; Schulz G; Kenn W; Richtmann H; Palitzsch KD; Jakob F
N Engl J Med; 2001 Dec; 345(26):1883-8. PubMed ID: 11756579
[No Abstract] [Full Text] [Related]
9. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.
Hu FK; Yuan F; Jiang CY; Lv DW; Mao BB; Zhang Q; Yuan ZQ; Wang Y
Chin J Cancer; 2011 Nov; 30(11):794-804. PubMed ID: 22035861
[TBL] [Abstract][Full Text] [Related]
10. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels.
Ishii A; Imanishi Y; Kobayashi K; Hashimoto J; Ueda T; Miyauchi A; Koyano HM; Kaji H; Saito T; Oba K; Komatsu Y; Kurajoh M; Nagata Y; Goto H; Wakasa K; Sugimoto T; Miki T; Inaba M; Nishizawa Y
Calcif Tissue Int; 2010 Jun; 86(6):455-62. PubMed ID: 20458578
[TBL] [Abstract][Full Text] [Related]
11. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
12. Tumor-induced Osteomalacia: A Systematic Review and Individual Patient's Data Analysis.
Rendina D; Abate V; Cacace G; D'Elia L; De Filippo G; Del Vecchio S; Galletti F; Cuocolo A; Strazzullo P
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3428-e3436. PubMed ID: 35468192
[TBL] [Abstract][Full Text] [Related]
13. [Hypophosphatemic osteomalacia].
Bullmann C; Benker G; Rosien U; Delling G; Siggelkow H; Schulte HM
Med Klin (Munich); 2008 Sep; 103(9):671-5. PubMed ID: 18813890
[TBL] [Abstract][Full Text] [Related]
14. Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Ovejero D; El-Maouche D; Brillante BA; Khosravi A; Gafni RI; Collins MT
J Bone Miner Res; 2017 Aug; 32(8):1667-1671. PubMed ID: 28459498
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-HYNIC-TOC (99mTc-hydrazinonicotinyl-Tyr3-octreotide) scintigraphy identifying two separate causative tumors in a patient with tumor-induced osteomalacia (TIO).
Jing H; Li F; Zhong D; Zhuang H
Clin Nucl Med; 2013 Aug; 38(8):664-7. PubMed ID: 23797229
[TBL] [Abstract][Full Text] [Related]
16. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.
Takeuchi Y; Suzuki H; Ogura S; Imai R; Yamazaki Y; Yamashita T; Miyamoto Y; Okazaki H; Nakamura K; Nakahara K; Fukumoto S; Fujita T
J Clin Endocrinol Metab; 2004 Aug; 89(8):3979-82. PubMed ID: 15292336
[TBL] [Abstract][Full Text] [Related]
17. Concordance between whole-body scintigraphy 111In-octreotide and 99mTc-sestamibi uptake in the detection of four tumor-induced osteomalacia cases.
Ferraz MP; Watanabe T; Sado HN; Ono CR; Buchpiguel CA; Correa PH; Martin RM
J Clin Endocrinol Metab; 2014 Mar; 99(3):699-700. PubMed ID: 24423352
[No Abstract] [Full Text] [Related]
18. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT.
Clifton-Bligh RJ; Hofman MS; Duncan E; Sim IeW; Darnell D; Clarkson A; Wong T; Walsh JP; Gill AJ; Ebeling PR; Hicks RJ
J Clin Endocrinol Metab; 2013 Feb; 98(2):687-94. PubMed ID: 23295468
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt.
Seemann L; Padala SA; Mohammed A; Belayneh N
J Investig Med High Impact Case Rep; 2019; 7():2324709619895162. PubMed ID: 31850815
[TBL] [Abstract][Full Text] [Related]
20. Tumour-induced osteomalacia: a literature review and a case report.
Dadoniene J; Miglinas M; Miltiniene D; Vajauskas D; Seinin D; Butenas P; Kacergius T
World J Surg Oncol; 2016 Jan; 14(1):4. PubMed ID: 26744291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
